Close Menu

NEW YORK (GenomeWeb) – The Cellworks Group has announced the results of clinical studies that showed how physicians could leverage the firm's computational biology modeling technology for genomic profiling of tumors and predicting patient response to chemotherapies.

In a prospective clinical study, called iCare 1, the Cellworks artificial intelligence-based technology was 90 percent accurate in predicting the response to standard-of-care treatments in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.